Is Retatrutide FDA Approved? Status and Release Date (2026)

The Short Answer

No, retatrutide is not approved. As of September 2026, retatrutide has not been approved by any regulatory authority in the world, including the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other national regulatory body. It remains an investigational compound in Phase 3 clinical development. It has no brand name, is not available by prescription, and cannot be legally purchased from any pharmacy or licensed distributor.

This is one of the most frequently asked questions about retatrutide, driven by media coverage of five positive Phase 3 readouts in 2025-2026: TRIUMPH-4 (December 2025, -28.7% weight loss at 12 mg in obesity with knee OA), TRANSCEND-T2D-1 (published in The Lancet June 6, 2026: HbA1c -1.9 points and -15.3% weight loss at 12 mg in type 2 diabetes), TRIUMPH-1 (May 21, 2026, -28.3% at 12 mg over 80 weeks in 2,339 adults with obesity but no diabetes), and on July 23, 2026 TRIUMPH-2 (-20.8% in obesity with type 2 diabetes) and TRIUMPH-3 (-22.6% in severe obesity with cardiovascular disease). Even with the pivotal program complete, approval requires a regulatory submission and FDA review. Eli Lilly has said it will submit a Biologics License Application (BLA) in the first quarter of 2027; nothing has been filed yet.

Why Is Retatrutide Not Yet Approved?

The Drug Development Process

To understand why retatrutide is not yet available, it is helpful to understand the standard drug development pathway. In the United States, the FDA requires that new drugs pass through a series of clinical development phases before they can be considered for approval:

• Phase 1: Small studies in healthy volunteers or patients to assess safety, tolerability, and pharmacokinetics. Retatrutide completed Phase 1 studies.
• Phase 2: Moderate-sized studies to evaluate efficacy, determine optimal dosing, and further characterize safety. Retatrutide completed Phase 2 studies with positive results published in the New England Journal of Medicine (obesity) and The Lancet (type 2 diabetes).
• Phase 3: Large, pivotal studies involving thousands of participants designed to confirm efficacy, establish the safety profile in a broader population, and generate the data required for regulatory submission. Retatrutide is currently in this phase.
• Regulatory review: After Phase 3 completion, the sponsor (Eli Lilly) submits a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA, which then reviews the complete data package and decides whether to approve the drug.

Retatrutide has now completed its pivotal Phase 3 program: TRIUMPH-1, -2, -3 and -4 and TRANSCEND-T2D-1 have all reported positive results. No application has been filed yet. Eli Lilly stated on July 23, 2026 that it plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027 for obesity, obstructive sleep apnea and knee osteoarthritis pain, and on August 5, 2026 that the clinical data package is complete and the remaining work is manufacturing (CMC) data. Lilly’s choice of a BLA rather than an NDA reflects its position that the 41-amino-acid peptide is a biologic; the FDA has contested that classification in court (Eli Lilly v. Kennedy, on appeal to the Seventh Circuit), so the application type could still change.

What Phase 3 Must Demonstrate

The Phase 3 program must accomplish several objectives before regulatory submission can proceed:

• Confirm efficacy in large, diverse patient populations for each intended indication (obesity, type 2 diabetes, and potentially MASH)
• Establish the safety profile with sufficient statistical power to detect uncommon adverse events — including characterizing the dysesthesia signal found in TRIUMPH-4
• Characterize long-term effects over treatment durations longer than the 48 weeks studied in Phase 2
• Identify the optimal dose and escalation regimen for clinical use
• Evaluate effects in special populations including older adults, patients with renal impairment, and patients with cardiovascular disease

What “Phase 3” Means for Patients

Phase 3 is the final stage of clinical development before regulatory submission. Being in Phase 3 means:

• The drug has shown promise: Phase 2 data were positive enough to justify the substantial investment in a large Phase 3 program
• Large-scale testing is underway: Thousands of participants are being treated across multiple countries and clinical sites
• Approval is not guaranteed: Historically, approximately 50-60% of drugs that enter Phase 3 ultimately receive FDA approval. Positive Phase 3 results increase the probability substantially, but unforeseen safety issues, insufficient efficacy, or manufacturing problems can still prevent approval
• The timeline is measurable: Unlike earlier development stages, Phase 3 trials have defined endpoints and estimated completion dates, making timeline projections more reliable

For patients, Phase 3 status means the drug is progressing but is still years away from commercial availability.

The TRIUMPH Phase 3 Program

Program Overview

Eli Lilly’s Phase 3 clinical program for retatrutide is known as TRIUMPH. It is one of the largest metabolic drug development programs currently underway, consisting of multiple clinical trials evaluating retatrutide across different indications and patient populations:

• TRIUMPH-1 through TRIUMPH-4: Four pivotal trials evaluating retatrutide for obesity and weight-related conditions
• TRIUMPH-Outcomes: ~10,000-patient cardiovascular outcomes trial (CVOT)
• TRANSCEND: Type 2 diabetes program (TRANSCEND-T2D-1, TRANSCEND-T2D-2 head-to-head vs semaglutide, and TRANSCEND-CKD)
• SYNERGY / MACELD: Trials for metabolic dysfunction-associated steatohepatitis (MASH), with histological endpoints

TRIUMPH-4: First Phase 3 Results (December 2025)

TRIUMPH-4 was the first trial in the program to report results. It enrolled 445 adults with obesity and knee osteoarthritis and demonstrated:

• Retatrutide 12 mg: -28.7% mean weight loss at 68 weeks
• Retatrutide 9 mg: -26.4% mean weight loss at the same timepoint
• 99% of participants at 12 mg achieved at least 5% weight loss
• 75% reduction in knee osteoarthritis pain scores
• New safety finding: dysesthesia (numbness, tingling, burning sensations) in 20.9% at 12 mg versus 0.7% placebo

TRANSCEND-T2D-1 (March 19, 2026)

Positive topline results were announced via Eli Lilly press release on March 19, 2026 and elaborated at the Q1 2026 earnings call on April 30:

• HbA1c reductions of 1.7-2.0 percentage points across doses — glycemic control comparable to tirzepatide
• Weight loss of 11.5-16.8% across doses (n=537, 40 weeks)
• Dysesthesia 2.3-4.5% across doses (lower than the obesity trials)
• The combination of glycemic control plus additional weight loss is what management framed as the clinically meaningful retatrutide differentiator versus tirzepatide in the T2D population

TRIUMPH-1: Pivotal Obesity Trial (May 21, 2026)

The largest readout to date — the obesity-indication-anchor trial:

• Retatrutide 12 mg: -28.3% mean weight loss (efficacy estimand) at 80 weeks in 2,339 adults with obesity but no diabetes
• 45.3% of 12 mg participants achieved ≥30% weight loss — bariatric-surgery territory
• 65.3% ended the trial with BMI <30 (no longer obese)
• All three doses (4 mg, 9 mg, 12 mg) met the primary endpoint
• 104-week extension hit -30.3% in the BMI ≥35 subgroup
• Dysesthesia at 12 mg: 12.5% — substantially lower than TRIUMPH-4’s 20.9% at the same dose
• Discontinuation due to AEs at 12 mg: 11.3% — also lower than TRIUMPH-4’s 18.2%

Remaining Trials

On July 23, 2026 Eli Lilly reported the final two pivotal obesity trials. TRIUMPH-2 (1,152 adults with obesity and type 2 diabetes, 80 weeks) showed -20.8% mean weight loss at 12 mg versus -4.0% on placebo, with A1C reductions of 1.4 to 1.6 points. TRIUMPH-3 (1,949 adults with BMI 35 or higher and established cardiovascular disease, 80 weeks) showed -22.6% at 12 mg versus -3.2%. Dysesthesia at 12 mg was 7.3% and 6.4% respectively, well below the 20.9% seen in TRIUMPH-4. Details: TRIUMPH-2 and TRIUMPH-3 results. The TRIUMPH-Outcomes cardiovascular outcomes trial, TRANSCEND-T2D-2 and the SYNERGY/MACELD MASH trials run on longer timelines and are not needed for the initial obesity submission.

Expected Timeline for Approval

Realistic Projections

Based on the current status of the TRIUMPH program:

These projections carry significant uncertainty. Delays in enrollment, unexpected safety findings, FDA requests for additional data, or manufacturing issues could all extend the timeline. Conversely, breakthrough therapy designation or rolling submission could shorten it.

Comparison to Tirzepatide’s Timeline

Eli Lilly’s tirzepatide (Mounjaro/Zepbound) provides a useful comparison:

• SURMOUNT-1 Phase 3 obesity data published: mid-2022
• Zepbound FDA approval for obesity: November 2023
• Time from Phase 3 data to obesity approval: approximately 17 months

However, tirzepatide benefited from prior diabetes approval (Mounjaro, May 2022), which established its safety database. Retatrutide does not have this advantage, as it has never been approved for any indication.

FDA Review Process

Once Eli Lilly submits the BLA, the FDA review follows a structured process:

• 60-day filing review: FDA determines if the application is complete enough to accept
• Standard Review: 10-12 months from acceptance to decision
• Priority Review: 6-8 months, granted when the drug offers significant improvement over existing treatments
• Advisory Committee: The FDA may convene external experts to evaluate the benefit-risk profile, particularly given the novel triple receptor mechanism and the dysesthesia signal

How to Access Retatrutide Today

Clinical Trials Are the Only Legitimate Route

The only way to receive retatrutide is through enrollment in an authorized clinical trial. Steps to explore this option:

1. Visit ClinicalTrials.gov and search for “retatrutide” or “LY3437943”
2. Review the list of active trials and their eligibility criteria
3. Discuss potential participation with your healthcare provider
4. Contact the study sites listed for trials that may be appropriate

Clinical trial participation involves its own considerations: randomization (you may receive placebo), strict visit schedules, monitoring requirements, and eligibility criteria that may exclude many individuals.

What Clinical Trial Participation Involves

Participants in TRIUMPH trials typically undergo:

• Screening assessments to verify eligibility
• Regular clinic visits (often monthly) for injections, lab work, and assessments
• Possibility of receiving placebo rather than active drug
• Long treatment periods (68+ weeks for most pivotal trials)
• Follow-up after treatment completion

Warning About Illegitimate Sources

The Problem of Gray-Market Peptides

The significant public interest in retatrutide has created a market for unregulated peptide products claiming to be retatrutide. These products are available from various online sources, including research chemical suppliers, compounding pharmacies operating outside standard regulatory oversight, and international vendors. These products pose significant risks:

• No quality assurance: Unregulated products are not manufactured under Good Manufacturing Practice (GMP) conditions. There is no guarantee of purity, potency, sterility, or even identity. Independent analyses of gray-market peptides have consistently found contamination, incorrect potency, and mislabeling.
• Unknown safety: Without manufacturing controls, these products may contain impurities, endotoxins, or degradation products that pose health risks independent of the active peptide.
• No medical supervision: Individuals using unregulated products typically do so without dose titration or safety monitoring. This is particularly concerning for a triple receptor agonist that affects glucose metabolism, heart rate, and gastrointestinal function — and which has now shown a 21% dysesthesia rate at the 12 mg dose in Phase 3.
• Legal concerns: The sale of unapproved drug products is illegal in many jurisdictions. Products shipped internationally may be seized at customs.

Compounding Pharmacy Warning

Unlike semaglutide and tirzepatide, which have been subject to FDA drug shortage designations that temporarily allowed certain compounding, retatrutide has never been approved and therefore is not listed in any drug shortage database. Compounding pharmacies that produce products labeled as retatrutide are operating entirely outside the regulatory framework.

There is no legitimate basis for any compounding pharmacy to produce retatrutide. Any such product:

• Is not FDA-approved or FDA-regulated
• Has not been tested for safety, purity, or efficacy
• May not contain retatrutide at all, or may contain incorrect quantities
• Carries unknown impurity and contamination risks

Our Recommendation

This publication does not endorse or encourage the use of retatrutide from any source other than authorized clinical trials. The risk-benefit calculation for an investigational drug can only be properly assessed within a clinical trial framework where participants receive properly manufactured drug product, undergo appropriate screening and monitoring, and contribute to the data that will ultimately inform regulatory decisions.

What Should Patients Do Now?

While waiting for retatrutide to potentially become available, patients interested in effective weight management have several options:

• FDA-approved medications: Semaglutide (Wegovy), tirzepatide (Zepbound), and other approved anti-obesity medications are available by prescription
• Clinical trials: Beyond retatrutide, numerous obesity clinical trials are enrolling participants for various investigational treatments
• Comprehensive care: Behavioral modification, dietary counseling, and exercise programs remain foundational to weight management
• Discuss with your provider: Healthcare professionals can help develop a treatment plan using currently available options while monitoring the retatrutide development timeline

Frequently Asked Questions

Can my doctor prescribe retatrutide?

No. Because retatrutide is not approved, it cannot be prescribed. It is available only through authorized clinical trials.

When will retatrutide be available?

The earliest realistic availability is late 2027 if the FDA grants Priority Review, and more likely the first half of 2028 under standard review, based on Eli Lilly’s plan to submit a BLA in Q1 2027. Commercial launch would follow approval. This timeline is subject to change with the FDA’s filing decision and review.

Is retatrutide the same as tirzepatide?

No. While both are incretin-based peptide therapies developed by Eli Lilly, they are different molecules. Tirzepatide (marketed as Mounjaro and Zepbound) is a dual GIP/GLP-1 receptor agonist that is approved and commercially available. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist that remains investigational.

Are the peptides sold online legitimate?

Products sold as retatrutide outside of clinical trials are not approved pharmaceutical products. Their quality, purity, and safety cannot be assured, and their use carries significant risks. There is no FDA drug shortage designation for retatrutide, so compounding pharmacies have no regulatory basis to produce it.

Did TRIUMPH-4 results mean approval is coming soon?

TRIUMPH-4 demonstrated impressive efficacy (-28.7% weight loss), but one Phase 3 trial was never going to be enough. The full program has since reported (TRIUMPH-1 in May 2026, TRIUMPH-2 and TRIUMPH-3 in July 2026), and Eli Lilly plans to file a BLA in Q1 2027. Approval could come as early as late 2027 with Priority Review, or in the first half of 2028 under standard review.

The FDA Regulatory Pathway in Detail

Marketing Application Requirements (BLA)

For retatrutide to receive FDA approval, Eli Lilly must submit a marketing application containing comprehensive data on the drug’s chemistry, manufacturing, and controls (CMC); nonclinical pharmacology and toxicology; clinical pharmacology and pharmacokinetics; and clinical efficacy and safety from the Phase 3 pivotal trials. Lilly has said the application will be a Biologics License Application (BLA) rather than a New Drug Application. The distinction matters commercially: a biologic receives 12 years of data exclusivity rather than five and is outside the pharmacy-compounding provisions that apply to drugs. The FDA has disputed whether the 41-amino-acid peptide meets the statutory definition of a protein; a district court sided partly with each side and Lilly’s appeal (Eli Lilly v. Kennedy) is before the Seventh Circuit, with oral argument scheduled for September 24, 2026. Whichever application type is used, the data package must demonstrate that retatrutide is safe and effective for its proposed indications and that its benefits outweigh its risks.

Obesity Indication

For approval as an anti-obesity medication, the FDA’s guidance (Developing Products for Weight Management, 2007) requires that a drug demonstrate one of the following:

• A statistically significant difference in mean weight loss from baseline compared to placebo, with the active treatment group achieving at least 5% mean weight loss
• A statistically significant difference in the proportion of participants achieving at least 5% weight loss, with at least 35% of the active treatment group reaching this threshold and approximately double the rate in the placebo group

Based on Phase 2 data, retatrutide substantially exceeds these thresholds, and two Phase 3 readouts have reinforced this position. TRIUMPH-4 (December 2025), a 68-week study in 445 adults with obesity and knee osteoarthritis, reported 28.7% mean weight loss at 12 mg and 26.4% at 9 mg, with all primary and key secondary endpoints met. TRIUMPH-1 (May 21, 2026), the pivotal obesity trial in 2,339 adults without diabetes, reported 28.3% mean weight loss at 12 mg over 80 weeks (efficacy estimand), with all three doses (4 mg / 9 mg / 12 mg) meeting primary endpoints. Notably, the dysesthesia rate at 12 mg in TRIUMPH-1 was 12.5% — substantially lower than the 20.9% reported in TRIUMPH-4 at the same dose, likely reflecting the lower-comorbidity TRIUMPH-1 population. The 104-week extension showed weight loss continuing to -30.3% in the BMI ≥35 subgroup.

Type 2 Diabetes Indication

For approval as a treatment for type 2 diabetes, the FDA requires demonstration of clinically meaningful improvement in glycemic control, typically assessed by reduction in HbA1c from baseline compared to placebo or an active comparator. The TRANSCEND-T2D-1 trial reported positive topline results on March 19, 2026 (Eli Lilly press release): HbA1c reductions of 1.7-2.0 percentage points and weight loss of 11.1-16.6 kg across doses — glycemic control comparable to tirzepatide with additional weight loss. TRIUMPH-2 (obesity + type 2 diabetes), which addresses both indications in a single trial, reported on July 23, 2026: -20.8% weight loss and an A1C reduction of 1.5 points at 12 mg over 80 weeks.

Cardiovascular Safety

The FDA’s 2008 Guidance for Industry on evaluating cardiovascular risk for diabetes drugs requires that the upper bound of the 95% confidence interval for the estimated risk ratio of major adverse cardiovascular events (MACE) not exceed 1.8 for pre-approval and 1.3 for post-marketing. Depending on the cardiovascular safety data accumulated during the Phase 3 program, Eli Lilly may need to conduct a dedicated cardiovascular outcomes trial (CVOT) either pre-approval or as a post-marketing requirement.

Expedited Pathways

Retatrutide may qualify for one or more FDA expedited review pathways:

• Fast Track Designation: Available for drugs that treat serious conditions and fill an unmet medical need. Given the severity of obesity and the potential for retatrutide to offer superior efficacy, Fast Track designation is plausible.
• Breakthrough Therapy Designation: Available for drugs that demonstrate substantial improvement over existing therapies based on preliminary clinical evidence. The Phase 2 weight loss data could support a Breakthrough Therapy application, though it is not publicly confirmed whether Eli Lilly has sought or received this designation for retatrutide.
• Priority Review: Available for drugs that offer significant improvements in treatment, safety, or effectiveness. If granted, Priority Review reduces the FDA’s review target from 10 months to 6 months.

International Regulatory Landscape

European Medicines Agency (EMA)

The European regulatory pathway operates through the EMA’s centralized procedure, which provides marketing authorization valid across all EU member states. Eli Lilly would submit a Marketing Authorisation Application (MAA) based on the same Phase 3 data package used for the FDA BLA, supplemented with any Europe-specific requirements. The EMA’s Committee for Medicinal Products for Human Use (CHMP) evaluates the application and issues an opinion, which is then adopted by the European Commission.

European approval timelines typically lag behind FDA approval by 6-12 months, reflecting the different regulatory processes and review timelines.

Other Markets

Regulatory submissions in other major markets, including Japan (PMDA), China (NMPA), Canada (Health Canada), and Australia (TGA), would follow each agency’s specific requirements. Eli Lilly typically pursues a global regulatory strategy with staggered submissions across major markets following initial FDA approval.

Regulatory Considerations for MASLD

The liver fat reduction observed in Phase 2 trials has raised the possibility of developing retatrutide for metabolic dysfunction-associated steatotic liver disease (MASLD) or its more severe form, metabolic dysfunction-associated steatohepatitis (MASH). The regulatory pathway for MASLD/MASH therapies is distinct from obesity and diabetes:

• The FDA has accepted conditional approval pathways based on histological endpoints (resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis)
• A separate clinical trial program with liver biopsy endpoints would be required
• The first MASH therapy (resmetirom) received FDA accelerated approval in 2024, establishing regulatory precedent

Eli Lilly is actively pursuing a MASLD/MASH indication for retatrutide. The SYNERGY trial evaluates retatrutide for MASH with histological endpoints, and the MACELD trial is also underway. Both trials are currently active as of September 2026.

Post-Marketing Requirements

If approved, retatrutide would be subject to ongoing regulatory obligations:

• Risk Evaluation and Mitigation Strategy (REMS): Depending on the safety profile, the FDA may require a REMS program to ensure that the benefits outweigh the risks
• Post-marketing safety surveillance: Mandatory reporting of adverse events observed in clinical practice
• Post-marketing studies: The FDA may require additional studies to evaluate long-term safety, use in specific populations, or cardiovascular outcomes
• Label updates: The prescribing information would be updated as new safety and efficacy data emerge

Summary

Retatrutide is not approved by any regulatory authority as of September 2026. Its pivotal Phase 3 program is complete, with five positive readouts (TRIUMPH-4, TRANSCEND-T2D-1, TRIUMPH-1, TRIUMPH-2, TRIUMPH-3). Eli Lilly plans to submit a Biologics License Application in Q1 2027, with a potential FDA decision in late 2027 (Priority Review) or the first half of 2028 (standard review).

There is no legitimate commercial source for retatrutide. Outside of clinical trials, the only sanctioned route is Lilly’s narrow expanded access program for adults with severe, refractory obesity, which a treating physician must request. Individuals interested in retatrutide should consult ClinicalTrials.gov for trial enrollment opportunities, discuss currently approved treatment options with their healthcare providers, and avoid unregulated sources that pose substantial safety and quality risks. The FDA has issued multiple warning letters to compounders attempting to sell unapproved retatrutide; retatrutide does not qualify for 503A or 503B compounding exemptions.